常染色体显性遗传阿尔茨海默病的纵向认知与生物标志物变化
基于显性遗传阿尔茨海默病网络(DIAN)的纵向研究,对217名参与者进行平均2.7次临床、认知、脑脊液和神经影像评估,发现β-淀粉样蛋白最早变化(症状出现前25年),随后皮质代谢下降(约7-10年后)、认知和海马萎缩(约20年后)。纵向估计显示脑脊液p-tau181在症状附近显著下降,与横断面估计的持续升高不同。
要点
- 纵向β-淀粉样蛋白变化最早,始于估计症状出现前25年。
- 皮质代谢下降约在β-淀粉样蛋白变化后7-10年,认知和海马萎缩约在20年后。
- 脑脊液p-tau181纵向估计在症状附近显著下降,横断面估计早于纵向估计超过10年。
核心结论
- 这些纵向估计阐明了常染色体显性阿尔茨海默病症状前病理变化的序列和时间动态,有助于更好地理解该疾病。
- 生物标志物变化模式提示,一旦β-淀粉样蛋白沉积开始,额外病理可能在其后不到10年开始发展,但早于症状出现超过15年,这是旨在改变疾病进程的干预措施的重要考虑。
研究设计与样本
- 研究采用显性遗传阿尔茨海默病网络(DIAN)研究,对217名DIAN参与者进行纵向临床、认知、脑脊液和神经影像评估,平均2.7(±1.1)次访视。
- 使用线性混合效应模型评估每个指标相对于个体估计症状出现年份的变化,并比较突变携带者与非携带者。
主要发现
- 纵向β-淀粉样蛋白指标最先变化,始于估计症状出现前25年。
- 随后皮质代谢指标下降约7-10年后发生,认知和海马萎缩约20年后发生。
- 脑脊液p-tau181和tau的估计存在显著差异,横断面估计的升高比纵向估计早超过10年;纵向估计显示脑脊液p-tau181在症状附近显著下降,而非持续升高。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the onset, sequence, and rate of progression of comprehensive biomarker and clinical measures across the spectrum of Alzheimer disease (AD) using the Dominantly Inherited Alzheimer Network (DIAN) study and compare these to cross-sectional estimates. METHODS: We conducted longitudinal clinical, cognitive, CSF, and neuroimaging assessments (mean of 2.7 [±1.1] visits) in 217 DIAN participants. Linear mixed effects models were used to assess changes in each measure relative to individuals' estimated years to symptom onset and to compare mutation carriers and noncarriers. RESULTS: Longitudinal β-amyloid measures changed first (starting 25 years before estimated symptom onset), followed by declines in measures of cortical metabolism (approximately 7-10 years later), then cognition and hippocampal atrophy (approximately 20 years later). There were significant differences in the estimates of CSF p-tau181 and tau, with elevations from cross-sectional estimates preceding longitudinal estimates by over 10 years; further, longitudinal estimates identified a significant decline in CSF p-tau181 near symptom onset as opposed to continued elevations. CONCLUSION: These longitudinal estimates clarify the sequence and temporal dynamics of presymptomatic pathologic changes in autosomal dominant AD, information critical to a better understanding of the disease. The pattern of biomarker changes identified here also suggests that once β-amyloidosis begins, additional pathologies may begin to develop less than 10 years later, but more than 15 years before symptom onset, an important consideration for interventions meant to alter the disease course.
引用
- McDade E, Wang G, Gordon BA, et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology. 2018. PMID: 30217935. doi:10.1212/WNL.0000000000006277
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。